Geoffrey Yarranton

3.2k total citations
53 papers, 2.5k citations indexed

About

Geoffrey Yarranton is a scholar working on Molecular Biology, Genetics and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Geoffrey Yarranton has authored 53 papers receiving a total of 2.5k indexed citations (citations by other indexed papers that have themselves been cited), including 31 papers in Molecular Biology, 14 papers in Genetics and 9 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Geoffrey Yarranton's work include Bacterial Genetics and Biotechnology (10 papers), DNA Repair Mechanisms (9 papers) and Monoclonal and Polyclonal Antibodies Research (8 papers). Geoffrey Yarranton is often cited by papers focused on Bacterial Genetics and Biotechnology (10 papers), DNA Repair Mechanisms (9 papers) and Monoclonal and Polyclonal Antibodies Research (8 papers). Geoffrey Yarranton collaborates with scholars based in United States, United Kingdom and Tanzania. Geoffrey Yarranton's co-authors include Christopher Bebbington, Steven G. Sedgwick, Mark I. Cockett, Malcolm L. Gefter, C. R. Bebbington, Geoffrey R. Banks, M L Gefter, Ad Spanos, G. O. Humphreys and M K Robinson and has published in prestigious journals such as Nature, Proceedings of the National Academy of Sciences and Nucleic Acids Research.

In The Last Decade

Geoffrey Yarranton

52 papers receiving 2.4k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Geoffrey Yarranton United States 29 1.7k 656 321 254 251 53 2.5k
Hans‐Joachim Fritz Germany 27 2.8k 1.6× 948 1.4× 205 0.6× 404 1.6× 52 0.2× 62 3.3k
Detlev Behnke Germany 25 1.1k 0.7× 584 0.9× 112 0.3× 288 1.1× 52 0.2× 56 1.9k
Phuong Pham United States 31 2.7k 1.6× 821 1.3× 237 0.7× 120 0.5× 120 0.5× 83 4.0k
Bernard Allet Switzerland 35 2.2k 1.3× 897 1.4× 315 1.0× 817 3.2× 109 0.4× 60 4.2k
Yi Shi United States 31 2.3k 1.4× 195 0.3× 431 1.3× 151 0.6× 63 0.3× 69 3.2k
Barbara Lipińska Poland 30 1.7k 1.0× 724 1.1× 48 0.1× 261 1.0× 87 0.3× 82 2.7k
K Yamanaka Japan 16 1.4k 0.8× 711 1.1× 74 0.2× 293 1.2× 73 0.3× 25 1.8k
U.A. Ramagopal United States 27 1.1k 0.6× 287 0.4× 167 0.5× 157 0.6× 175 0.7× 53 2.6k
Václav Veverka Czechia 29 1.8k 1.1× 268 0.4× 173 0.5× 110 0.4× 93 0.4× 86 2.9k
M K Robinson United States 24 1.2k 0.7× 368 0.6× 380 1.2× 126 0.5× 49 0.2× 33 2.8k

Countries citing papers authored by Geoffrey Yarranton

Since Specialization
Citations

This map shows the geographic impact of Geoffrey Yarranton's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Geoffrey Yarranton with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Geoffrey Yarranton more than expected).

Fields of papers citing papers by Geoffrey Yarranton

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Geoffrey Yarranton. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Geoffrey Yarranton. The network helps show where Geoffrey Yarranton may publish in the future.

Co-authorship network of co-authors of Geoffrey Yarranton

This figure shows the co-authorship network connecting the top 25 collaborators of Geoffrey Yarranton. A scholar is included among the top collaborators of Geoffrey Yarranton based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Geoffrey Yarranton. Geoffrey Yarranton is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Charmsaz, Sara, Fares Al‐Ejeh, Trina Yeadon, et al.. (2016). EphA3 as a target for antibody immunotherapy in acute lymphoblastic leukemia. Leukemia. 31(8). 1779–1787. 28 indexed citations
2.
Vail, Mary E., Carmel Murone, Linda Hii, et al.. (2014). Targeting EphA3 Inhibits Cancer Growth by Disrupting the Tumor Stromal Microenvironment. Cancer Research. 74(16). 4470–4481. 67 indexed citations
3.
Legrand, Fanny, Nenad Tomas̆ević, Olga Šimáková, et al.. (2014). The eosinophil surface receptor epidermal growth factor–like module containing mucin-like hormone receptor 1 (EMR1): A novel therapeutic target for eosinophilic disorders. Journal of Allergy and Clinical Immunology. 133(5). 1439–1447.e8. 52 indexed citations
4.
Lancet, Jeffrey E., Andrew H. Wei, S. T. S. Durrant, et al.. (2013). A Phase I Study Of KB004, a Novel Non-Fucosylated humaneered® Antibody, Targeted Against The Receptor Tyrosine Kinase EphA3, In Advanced Hematologic Malignancies. Blood. 122(21). 3838–3838. 5 indexed citations
5.
Padron, Eric, Jeffrey S. Painter, Sateesh Kunigal, et al.. (2013). GM-CSF–dependent pSTAT5 sensitivity is a feature with therapeutic potential in chronic myelomonocytic leukemia. Blood. 121(25). 5068–5077. 108 indexed citations
6.
Song, Yuanlin, M Baer, Ramya Srinivasan, et al.. (2011). PcrV antibody–antibiotic combination improves survival in Pseudomonas aeruginosa-infected mice. European Journal of Clinical Microbiology & Infectious Diseases. 31(8). 1837–1845. 47 indexed citations
7.
Bebbington, Christopher & Geoffrey Yarranton. (2008). Antibodies for the treatment of bacterial infections: current experience and future prospects. Current Opinion in Biotechnology. 19(6). 613–619. 75 indexed citations
8.
Casey, Joanne L., Mark Napier, David J. King, et al.. (2002). Tumour targeting of humanised cross-linked divalent-fab′ antibody fragments: a clinical phase I/II study. British Journal of Cancer. 86(9). 1401–1410. 35 indexed citations
9.
Dubois, Vincent, Thomas J. Lobl, Cecilia Oliyai, et al.. (2002). CPI-0004Na, a new extracellularly tumor-activated prodrug of doxorubicin: in vivo toxicity, activity, and tissue distribution confirm tumor cell selectivity.. PubMed. 62(8). 2327–31. 26 indexed citations
10.
Trouet, A., A. Passioukov, R. Baurain, et al.. (2000). CPI-0004Na An extracellularly tumor-activated prodrug of doxorubicin. 41. 522. 1 indexed citations
11.
Casey, Joanne L., et al.. (1999). Dosimetric evaluation and radioimmunotherapy of anti-tumour multivalent Fab′ fragments. British Journal of Cancer. 81(6). 972–980. 23 indexed citations
12.
Cockett, Mark I., Christopher Bebbington, & Geoffrey Yarranton. (1991). The use of engineered E1A genes to transactivate the hCMV-MIE promoter in permanent CHO cell lines. Nucleic Acids Research. 19(2). 319–325. 56 indexed citations
13.
Kashmiri, S. V. S., David Colcher, F. James Primus, et al.. (1991). Generation and characterization of a recombinant/chimeric B72.3 (human gamma 1).. PubMed. 51(1). 181–9. 29 indexed citations
14.
Field, Hugh J., Geoffrey Yarranton, & Anthony R. Rees. (1990). Expression of mouse immunoglobulin light and heavy chain variable regions in Escherichia coli and reconstitution of antigen-binding activity. Protein Engineering Design and Selection. 3(7). 641–647. 31 indexed citations
15.
Lyons, A. Bruce, David J. King, Raymond J. Owens, et al.. (1990). Site-specific attachment to recombinant antibodies via introduced surface cysteine residues. Protein Engineering Design and Selection. 3(8). 703–708. 53 indexed citations
16.
Wright, Edwina M., G. O. Humphreys, & Geoffrey Yarranton. (1986). Dual-origin plasmids containing an amplifiable ColE1 ori; temperature-controlled expression of cloned genes. Gene. 49(3). 311–321. 25 indexed citations
17.
Yarranton, Geoffrey, Edwina M. Wright, M K Robinson, & G. O. Humphreys. (1984). Dual-origin plasmid vectors whose origin of replication is controlled by the coliphage lambda promoter pL. Gene. 28(3). 293–300. 26 indexed citations
18.
Yarranton, Geoffrey & Steven G. Sedgwick. (1982). Cloned truncated recA genes in E. coli. Molecular and General Genetics MGG. 185(1). 99–104. 59 indexed citations
19.
Spanos, Ad, Steven G. Sedgwick, Geoffrey Yarranton, Ulrich Hübscher, & Geoffrey R. Banks. (1981). Detection of the catalytic activities of DNA polymerases and their associated exonucleases following SDS-polyacrylamide gel electrophoresis. Nucleic Acids Research. 9(8). 1825–1839. 182 indexed citations
20.
Das, Ritam, Geoffrey Yarranton, & M L Gefter. (1980). Enzyme-catalyzed DNA unwinding. The role of ATP in helicase III activity.. Journal of Biological Chemistry. 255(17). 8069–8073. 11 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Hans‐Joachim Fritz Breakdown of academic impact, for papers by Detlev Behnke Breakdown of academic impact, for papers by Phuong Pham Breakdown of academic impact, for papers by Bernard Allet Breakdown of academic impact, for papers by Yi Shi Breakdown of academic impact, for papers by Barbara Lipińska Breakdown of academic impact, for papers by K Yamanaka Breakdown of academic impact, for papers by U.A. Ramagopal Breakdown of academic impact, for papers by Václav Veverka Breakdown of academic impact, for papers by M K Robinson
Rankless by CCL
2026